UNSPSC 51422206: Fluocinolone acetonide

This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0CD5FD6S2M. European Medicines Agency schedules Fluocinolone acetonide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07714MIG. Fluocinolone acetonide generally arises in the molecular formula C24H30F2O6.

The term FLUOCINOLONE ACETONIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, list 5.) Most nations schedule fluocinolone acetonide under HS 29372200 and SITC 54153. As of Q4 2014, FLUOCINOLONE ACETONIDE remains the US FDA Preferred Term for this commodity. Fluocinolone acetonide bears US NLM identifiers UMLS ID C0016298 and NCI Concept Code C29055. SMILES: FC12C(C3C(C4(OC(OC4C3)(C)C)C(=O)CO)(CC1O)C)CC(F)C1=CC(=O)C=CC21C.

UNSPSC 51422206 Fluocinolone acetonide, a Commodity code, shows a mismatch between its nominal scope and recent state and local procurement activity. The code designates a specific pharmaceutical active ingredient used in dermatologic and ophthalmic preparations, yet the recent opportunities tagged to this code reflect procurement of naloxone (an opioid antagonist used in overdose reversal) and exploratory market research into direct-to-manufacturer prescription fulfillment models — neither of which aligns with fluocinolone acetonide's therapeutic use or chemical class. State and local issuing bodies do purchase branded and generic pharmaceuticals and biologics through health departments, county health systems, and state health and human services agencies, but the tagged opportunities do not support meaningful activity under this specific commodity code.

The two recent opportunities present divergent procurement approaches. Seminole County, Florida issued IFB60459723LAS in June 2026 for naloxone and drug deactivation systems with a July 26, 2023 response deadline, seeking 1,900 units of naloxone and 800 deactivation systems annually through quarterly deliveries; the Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 as an exploratory market-intelligence instrument on direct-to-manufacturer pharmacy prescription programs with no formal award timeline or budget identified. The Seminole County opportunity uses a traditional competitive bidding structure (IFB) with fixed-price contracting, while the Texas RFI represents early-stage capability assessment preceding formal RFP issuance. Neither opportunity reflects procurement demand for fluocinolone acetonide specifically, suggesting the code assignment is administrative mislabeling rather than a signal of current market activity under this pharmaceutical commodity.